Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 22

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
148 Office equipment  40,812   37,604 Renovation  106,441   101,137 Signboard  806   806 Solar PV System  16,935   16,935 Machinery  190,880   190,341    2,515,194   2,506,143 (Less): Accumulated depreciation  (783,618)  (756,976)(Less): Accumulated impairment  (40,173)  (40,173)Add: Foreign translation differences  (171,124)  (186,004)Property, plant and equipment, net $1,520,279  $1,522,990  During the periods ended March 31, 2025 and 2024, the Company recorded depreciation of $26,642 and $20,138, respectively. 

 19Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 7 – INVESTMENTS IN EQUITY SECURITIES   As of    March 31,  December 31,   2025  2024 As of beginning of the period/year $1,265,166  $1,699,831 Addition during the period/year  -   492,732 Disposal during the period/year  -   (1,030,368)Fair value (loss)/gain  (63,983)  69,476 Foreign exchange translation   12,165   33,495 As of end of the period/year $1,213,348  $1,265,166  For the periods ended March 31, 2025 and 2024, the net fair value (loss)/gains on the investments in equity securities were $(63,983) and $40,488 recorded in other income of the Consolidated Statements of Operations and Comprehensive Income/(Loss).   The investments in equity securities consist of the following shares:          As of    March 31,  December 31,